OR WAIT null SECS
© 2021 MJH Life Sciences and Contemporary OB/GYN. All rights reserved.
© 2021 MJH Life Sciences™ and Contemporary OB/GYN. All rights reserved.
October 15, 2021
They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.
October 05, 2021
The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.